While there were no clinically significant differences in glycaemic control in meta-analyses that compared NPH and short-acting human insulins with long- and short-acting insulin analogues, respectively [33, 34], there was a lower risk of hypoglycaemia with long-acting insulin analogues than with NPH insulin [34]. The gene discussed is INS; the disease is Hypoglycemia.